Generation of patient-derived pluripotent stem cell-lines and CRISPR modified isogenic controls with mutations in the Parkinson's associated GBA gene

Stem Cell Res. 2022 Oct:64:102919. doi: 10.1016/j.scr.2022.102919. Epub 2022 Sep 15.

Abstract

The GBA gene encodes the lysosomal enzyme glucocerebrosidase (GCase), responsible for the hydrolysis of glucocerebroside to glucose and ceramide. Heterozygous GBA mutations have been associated with the development of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). We generated two induced pluripotent stem cell (iPSC) lines from PD patients carrying heterozygous GBA W378G or N370S mutations and subsequently produced isogenic control lines using CRISPR/Cas9 genome editing. The patient-derived iPSCs and isogenic control lines maintained full pluripotency, normal karyotypes, and differentiation capacity. All iPSC lines could be differentiated into dopaminergic neurons, thus providing valuable tools for studying PD pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glucose
  • Glucosylceramidase / genetics
  • Glucosylceramidase / metabolism
  • Glucosylceramides / metabolism
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Mutation / genetics
  • Parkinson Disease* / pathology

Substances

  • Glucose
  • Glucosylceramidase
  • Glucosylceramides
  • GBA protein, human

Grants and funding